{"filing":{"accession_number":"0001104659-26-105953","cik":"0001082554","ticker":"UTHR","company_name":"UNITED THERAPEUTICS Corp","form":"8-K","filing_date":"2026-09-08","report_date":"2026-09-08","primary_document":"tm2624887d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1082554/000110465926105953/tm2624887d1_8k.htm"},"events":[{"id":32078,"run_id":29467,"accession_number":"0001104659-26-105953","anchor_item_number":"1.01","event_type":"dividend_distribution","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"United Therapeutics entered into an accelerated share repurchase (ASR) agreement with Citibank to repurchase approximately $477.6 million of common stock, completing its previously announced $2 billion share repurchase program over approximately 2.5 years.","company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","filing_date":"2026-09-08","form":"8-K","submitted_at":null,"items":[{"id":35156,"accession_number":"0001104659-26-105953","item_number":"1.01","item_title":null,"event_type":"dividend_distribution","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"United Therapeutics entered into an accelerated share repurchase (ASR) agreement with Citibank to repurchase approximately $477.6 million of common stock under its previously announced $2 billion share repurchase program. Share repurchases are a form of capital return to shareholders and fall within the dividend_distribution category, which encompasses \"share-repurchase programs\" as explicitly stated in the taxonomy. The transaction is material, involving nearly half a billion dollars and representing the final tranche of a multi-billion dollar authorization completed over 2.5 years.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T21:13:42.118969+00:00","company_name":"","ticker":null,"filing_date":""},{"id":35157,"accession_number":"0001104659-26-105953","item_number":"7.01","item_title":null,"event_type":"dividend_distribution","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"United Therapeutics announced an Accelerated Share Repurchase (ASR) agreement for approximately $477.6 million to complete a $2 billion share repurchase authorization. Share repurchases are a form of capital return to shareholders and fall within the dividend_distribution category. The company explicitly states it will \"return $4 billion to our shareholders in approximately 2.5 years\" through this program, and the ASR represents a material deployment of capital ($477.6 million upfront) that would affect investor assessment of capital allocation and shareholder returns.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T21:13:42.118969+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35156,"accession_number":"0001104659-26-105953","item_number":"1.01","item_title":null,"event_type":"dividend_distribution","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"United Therapeutics entered into an accelerated share repurchase (ASR) agreement with Citibank to repurchase approximately $477.6 million of common stock under its previously announced $2 billion share repurchase program. Share repurchases are a form of capital return to shareholders and fall within the dividend_distribution category, which encompasses \"share-repurchase programs\" as explicitly stated in the taxonomy. The transaction is material, involving nearly half a billion dollars and representing the final tranche of a multi-billion dollar authorization completed over 2.5 years.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T21:13:42.118969+00:00","company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","filing_date":"2026-09-08"},{"id":35157,"accession_number":"0001104659-26-105953","item_number":"7.01","item_title":null,"event_type":"dividend_distribution","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"United Therapeutics announced an Accelerated Share Repurchase (ASR) agreement for approximately $477.6 million to complete a $2 billion share repurchase authorization. Share repurchases are a form of capital return to shareholders and fall within the dividend_distribution category. The company explicitly states it will \"return $4 billion to our shareholders in approximately 2.5 years\" through this program, and the ASR represents a material deployment of capital ($477.6 million upfront) that would affect investor assessment of capital allocation and shareholder returns.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T21:13:42.118969+00:00","company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","filing_date":"2026-09-08"}]}